Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer ...

Gross SC-islet morphology and size were maintained, yet the fraction of NKX6.1-positive β cells fell substantially, pointing ...

Survivorship care and patient follow-up, being pivotal to managing treatment plans for patients with breast cancer, were key ...

Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets ...

In the final episode, 'Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based Care,' the panelists ...

Approval covers all current IV isatuximab indications and introduces the first oncology product labeled for both OBI and manual SC administration. IRAKLIA (NCT05405166) established noninferiority of ...

Harrison noted that responses were observed across calreticulin mutation types and among patients with additional mutations, with minimal toxicity reported to date. She concluded by describing ...

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

In a recent podcast, Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, offered a candid account ...

Christina Poh confirmed that the disconnect between provider and patient experiences of shared decision-making resonates strongly with what she observes in clinical practice, noting that while care ...

COVID-19-related Medicare spending and health care use declined after acute infection, with minimal excess costs by weeks 13 to 40 after diagnosis.

ORIGIN 3 randomized 431 biopsy‑confirmed IgAN patients 1:1; atacicept 150 mg weekly SC produced the largest placebo‑adjusted UPCR reduction reported at week 36. Accelerated approval hinged on ...